Clicky

PhaseBio Pharmaceuticals, Inc.(PHAS)

Description: PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapies to treat orphan diseases with an initial focus on cardiopulmonary indications. Its lead product candidate, PB2452, is a reversal agent for the antiplatelet drug ticagrelor that has completed a Phase 1 clinical trial and is been developed for the treatment of patients on ticagrelor who are experiencing a major bleeding event or those who require urgent surgery. It is also developing PB1046, a fusion protein currently in a Phase 2b clinical trial for the treatment of pulmonary arterial hypertension. The company was founded in 2002 and is based in Malvern, Pennsylvania.


Keywords: Biopharmaceutical Surgery Organic Compounds Chemical Compounds Hypertension Pulmonary Arterial Hypertension Pulmonary Hypertension Orphan Disease Platelet Bio Pharmaceutical Fusion Protein Reversal Adenosine Diphosphate Receptor Inhibitor Antiplatelet Drug Ticagrelor Pb1046

Home Page: phasebio.com

PHAS Technical Analysis

1 Great Valley Parkway
Malvern, PA 19355
United States
Phone: 610 981 6500


Officers

Name Title
Mr. Jonathan P. Mow MBA Pres, CEO & Director
Mr. John P. Sharp CPA Chief Financial Officer
Dr. John S. Lee M.D., Ph.D. Chief Medical Officer
Ms. Susan Elizabeth Arnold Ph.D. Sr. VP of Technical Operations
Mr. Kristopher L. Hanson SVP, Gen. Counsel & Corp. Sec.
Mr. Glen G. Burkhardt Sr. VP of HR
Ms. Lauren Richardson Global Head of Regulatory Affairs & Quality Assurance
Mr. Jonathan J. Birchall Chief Commercial Officer

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 26.18
Price-to-Sales TTM: 4.2727
IPO Date: 2018-10-18
Fiscal Year End: December
Full Time Employees: 60
Back to stocks